Acumen Pharmaceuticals, Inc. (ABOS) vs Codexis, Inc. (CDXS)

A side-by-side comparison of Acumen Pharmaceuticals, Inc. and Codexis, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — ABOS vs CDXS

growth of $100 · dividends reinvested · last 5y
ABOS -89.4% (-36.2%/yr)CDXS -94.1% (-43.3%/yr)ABOS compounded faster over this window
050100150Start $10020222023202420252026$11$6
ABOS CDXS

ABOS vs CDXS: by the numbers

  • •CDXS is the larger company ($155M vs $148M market cap).
  • •Both run net losses; ABOS's is the smaller (0.00% vs -39.55% net margin).

Metrics side by side

Valuation

MetricABOSCDXS
P/S ratioN/A1.99
P/B ratio2.594.70

Profitability

MetricABOSCDXS
Gross margin0.00%83.71%
Operating margin0.00%-54.46%
Net margin0.00%-39.55%
ROE-183.44%-93.22%
ROIC-118.67%-23.41%

Growth (annualized)

MetricABOSCDXS
Revenue CAGR (5Y)N/A0.38%
Total return CAGR (5Y)-32.60%-44.64%

Frequently asked

How have ABOS and CDXS total returns compared?
Over the past 5 years, ABOS delivered -32.60% and CDXS delivered -44.64% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.